Floatz logo

Tbio-6517

Oropharynx Cancer

Turnstone Biologics, Corp.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

4 Active assets in the Oropharynx Cancer cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Turnstone Biologics, Corp.
Phase 2BB
e7 tcr-t cells
Christian Hinrichs
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2CCC
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
VM Oncology, LLC
Phase 1/2CCC

Same molecule, other indications

Tbio-6517 is also rated in:

colorectal cancerDormant
CC
Indicative ·
43 / 100
View asset →
oropharynx squamous cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
cutaneous melanomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →